NBD AI Bulletin - Jointown Pharmaceutical Group Co., Ltd. (the Company) issued a performance forecast on January 22, expecting net profit attributable to shareholders of the listed company in 2020 to be about 3.056 billion yuan~3.201 billion yuan, an increase of about 1.329 billion yuan~1.475 billion yuan or about 77%~85% compared with a year earlier.
Preliminary calculation by the finance department shows that net profit attributable to shareholders of the listed company after deducting the non-recurrent gains and losses is projected to increase by 312 million yuan~458 million yuan or by 20%~30% compared with the previous year to about 1.838 billion yuan~1.983 billion yuan.
The main reason for the change in performance are the steady increase of the main businesses, including the Company's general agency/distribution business, medical equipment and others, as well as the continually improved gross margin, reduced financing costs, policies for slashing taxes and fees, and enhanced management measures. The changes in fair value recognized in profit or loss brought by the litsing of invested company Imeik Technology Development Co., Ltd. on the ChiNext of the Shenzhen Stock Exchange and compensation from land disposal received by wholly-owned subsidiary Shanghai Jiuzhoutong Pharmaceutical Co., Ltd. resulted in a combined non-recurring gain of about 1.218 billion yuan for the Company, greatly pushing the Company's net profit for 2020.
Jointown Pharmaceutical Group Co, Ltd's chairman is Liu Baolin, male, Chinese national, no permanent residence abroad, college degree, senior economist. The Company's general manager is Liu Yichang, male, Chinese national, no permanent residence abroad, undergraduate degree in business administration.
Tips on "Stock Trends":
1. The number of shares held by northbound investors in the Company increased by 6.6853 million in the past 30 days, representing 0.36% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.